Literature DB >> 26369986

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.

K Wenn1, L Tomala1, S Wilop1, L Vankann1, C Hasenbank1, O Frank2, A Hochhaus3, F J Giles4, T Lange5, M C Müller6, S Koschmieder1, F Beier1, P Ziegler1,7, T H Brümmendorf1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26369986     DOI： 10.1038/leu.2015.245

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.

Authors:  Tim H Brümmendorf; Inci Ersöz; Ulrike Hartmann; Kerol Bartolovic; Stefan Balabanov; Alexandra Wahl; Peter Paschka; Sebastian Kreil; Tanja Lahaye; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rüdiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Journal:  Blood       Date:  2003-01-01       Impact factor: 22.113

2.  Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.

Authors:  Patrick Ziegler; Hubert Schrezenmeier; Jamil Akkad; Ute Brassat; Lucia Vankann; Jens Panse; Stefan Wilop; Stefan Balabanov; Klaus Schwarz; Uwe M Martens; Tim H Brümmendorf
Journal:  Ann Hematol       Date:  2012-04-04       Impact factor: 3.673

3.  Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.

Authors:  T H Brümmendorf; T L Holyoake; N Rufer; M J Barnett; M Schulzer; C J Eaves; A C Eaves; P M Lansdorp
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

4.  Epigenetic aging upon allogeneic transplantation: the hematopoietic niche does not affect age-associated DNA methylation.

Authors:  C I Weidner; P Ziegler; M Hahn; T H Brümmendorf; A D Ho; P Dreger; W Wagner
Journal:  Leukemia       Date:  2014-11-12       Impact factor: 11.528

Review 5.  The telomere syndromes.

Authors:  Mary Armanios; Elizabeth H Blackburn
Journal:  Nat Rev Genet       Date:  2012-09-11       Impact factor: 53.242

6.  Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

Authors:  J E Sokal; E B Cox; M Baccarani; S Tura; G A Gomez; J E Robertson; C Y Tso; T J Braun; B D Clarkson; F Cervantes
Journal:  Blood       Date:  1984-04       Impact factor: 22.113

7.  Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.

Authors:  Mark Drummond; Anne Lennard; Tim Brûmmendorf; Tessa Holyoake
Journal:  Leuk Lymphoma       Date:  2004-09

Review 8.  Concise review: Telomere biology in normal and leukemic hematopoietic stem cells.

Authors:  Mark W Drummond; Stefan Balabanov; Tessa L Holyoake; Tim H Brummendorf
Journal:  Stem Cells       Date:  2007-05-17       Impact factor: 6.277

9.  Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.

Authors:  Tim H Brummendorf; Inci Ersoz; Ulrike Hartmann; Stefan Balabanov; Holger Wolke; Peter Paschka; Tanja Lahaye; Birgit Berner; Kerol Bartolovic; Sebastian Kreil; Ute Berger; Harald Gschaidmeier; Carsten Bokemeyer; Rudiger Hehlmann; Klaus Dietz; Peter M Lansdorp; Lothar Kanz; Andreas Hochhaus
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

10.  Direct comparison of flow-FISH and qPCR as diagnostic tests for telomere length measurement in humans.

Authors:  Fernanda Gutierrez-Rodrigues; Bárbara A Santana-Lemos; Priscila S Scheucher; Raquel M Alves-Paiva; Rodrigo T Calado
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240
View more
  4 in total

1.  Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Authors:  Anne-Sophie Bouillon; Monica S Ventura Ferreira; Shady Adnan Awad; Johan Richter; Andreas Hochhaus; Volker Kunzmann; Jolanta Dengler; Jeroen Janssen; Gert Ossenkoppele; Peter E Westerweel; Peter A W Te Boekhorst; Francois-Xavier Mahon; Henrik Hjorth-Hansen; Susanne Isfort; Thoas Fioretos; Sebastian Hummel; Mirle Schemionek; Stefan Wilop; Steffen Koschmieder; Susanne Saußele; Satu Mustjoki; Fabian Beier; Tim H Brümmendorf
Journal:  Blood Adv       Date:  2018-07-10

2.  Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy.

Authors:  Sigrid Hatse; Marta Serena; Christof Vulsteke; Kevin Punie; Patrick Neven; Ann Smeets; Annouschka Laenen; Hans Wildiers
Journal:  Transl Oncol       Date:  2022-10-08       Impact factor: 4.803

Review 3.  Telomeres and Telomerase in Hematopoietic Dysfunction: Prognostic Implications and Pharmacological Interventions.

Authors:  Theresa Vasko; Andrea Kaifie; Matthias B Stope; Thomas Kraus; Patrick Ziegler
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

4.  Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.

Authors:  Benjamin Rolles; Joao Gorgulho; Mareike Tometten; Christoph Roderburg; Margherita Vieri; Anne Abels; Mihael Vucur; Felix Heymann; Frank Tacke; Tim H Brümmendorf; Tom Luedde; Fabian Beier; Sven H Loosen
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.